Brigimadlin
Brigimadlin[edit | edit source]
Brigimadlin is a small molecule inhibitor that targets the MDM2 protein, which is a negative regulator of the tumor suppressor protein p53. By inhibiting MDM2, brigimadlin aims to restore the tumor-suppressing function of p53, thereby inducing apoptosis in cancer cells. This mechanism of action makes brigimadlin a potential therapeutic agent in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
Brigimadlin functions by binding to the MDM2 protein, which is known to ubiquitinate and degrade p53 under normal physiological conditions. In many cancers, the overexpression of MDM2 leads to the inactivation of p53, allowing cancer cells to proliferate unchecked. By inhibiting MDM2, brigimadlin prevents the degradation of p53, leading to the accumulation of active p53 in the cell. This activation of p53 can result in cell cycle arrest and apoptosis, particularly in cancer cells that retain wild-type p53.
Clinical Development[edit | edit source]
Brigimadlin is currently under investigation in various clinical trials to assess its efficacy and safety in treating different types of cancer. These trials are exploring its use as a monotherapy as well as in combination with other anticancer agents. The primary focus is on cancers that are known to have functional p53 but are driven by MDM2 overexpression.
Potential Applications[edit | edit source]
The therapeutic potential of brigimadlin is being explored in several types of cancer, including:
- Acute myeloid leukemia (AML)
- Liposarcoma
- Solid tumors with MDM2 amplification
The ability of brigimadlin to reactivate p53 makes it a promising candidate for cancers that are resistant to conventional therapies.
Side Effects and Safety[edit | edit source]
As with many anticancer agents, brigimadlin may have side effects. Commonly observed adverse effects in clinical trials include:
The safety profile of brigimadlin is still being evaluated, and ongoing studies aim to better understand the risk-benefit ratio of this drug.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
